



Wilson, R. A.M., Evans, T.R. J. , Fraser, A. R. and Nibbs, R. J.B. (2018) Immune checkpoint inhibitors: new strategies to checkmate cancer. *Clinical and Experimental Immunology*, 191(2), pp. 133-148.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.


Wilson, R. A.M., Evans, T.R. J. , Fraser, A. R. and Nibbs, R. J.B. (2018) Immune checkpoint inhibitors: new strategies to checkmate cancer. *Clinical and Experimental Immunology*, 191(2), pp. 133-148. (doi:[10.1111/cei.13081](https://doi.org/10.1111/cei.13081))

This article may be used for non-commercial purposes in accordance with [Wiley Terms and Conditions for Self-Archiving](#).

<http://eprints.gla.ac.uk/151931/>

Deposited on: 29 November 2017

Immune Checkpoint Inhibitors: New strategies to checkmate cancer.

Ruairi A. M. Wilson¹, T. R. Jeffrey Evans^{3,4}, Alasdair R. Fraser^{1,2} , Robert J. B. Nibbs¹

¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow; ²Advanced Therapeutics, Scottish National Blood Transfusion Service, Edinburgh; ³Cancer Research UK Beatson Institute, Glasgow; ⁴Institute of Cancer Sciences, University of Glasgow, Glasgow.

Corresponding Author: Robert Nibbs, Sir Graeme Davies Building, 120 University Place, University of Glasgow, Glasgow G12 8TA, UK. Email: robert.nibbs@glasgow.ac.uk

Key Words: Tumour immunology; T-cell; cancer; antibodies

List of abbreviations:

APC: Antigen-presenting cell

Treg: Regulatory T-cell

CR: Complete response

CTLA-4: Cytotoxic T-lymphocyte-associated protein 4

DC: Dendritic cell

FcγR: Fragment crystalline gamma receptor

FDA: Food and Drug Administration (U.S)

IAE: Immune-related adverse effect

ICI: Immune checkpoint inhibitor

NSCLC: Non-small cell lung cancer

ORR: Overall response ratio

OS: Overall survival

PD-L1/L2: Programmed cell death ligand 1/2

PD-1: Programmed cell death protein 1

PR: Partial response

RCC: Renal cell carcinoma

SCLC: Small cell lung cancer

TME: Tumour microenvironment

nTreg: Naturally-occurring regulatory T-cell

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1111/cei.13081

This article is protected by copyright. All rights reserved.

Abstract.

Immune checkpoint inhibitors (ICIs) targeting Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4) or Programmed cell Death protein 1 (PD-1) receptors have demonstrated remarkable efficacy in subsets of patients with malignant disease. This emerging treatment modality holds great promise for future cancer treatment and has engaged pharmaceutical research interests in tumour immunology. While ICIs can induce rapid and durable responses in some patients, identifying predictive factors for effective clinical responses has proven challenging. This review summarises the mechanisms of action of ICIs and outlines important pre-clinical work that contributed to their development. We explore clinical data that has led to disease-specific drug licensing, and highlight key clinical trials that have revealed ICI efficacy across a range of malignancies. We describe how ICIs have been used as part of combination therapies, and explore their future prospects in this area. We conclude by discussing the incorporation of these new immunotherapeutics into precision approaches to cancer therapy.

Introduction.

There are extensive interactions between tumour cells and the components of the immune system. The process of immune surveillance ensures that aberrant cells with tumorigenic potential can undergo immune destruction before they develop into cancers, and from the very earliest stages of tumour development the tumour microenvironment (TME) contains often-substantial populations of leukocytes, including various subsets of T-cells [1, 2]. Effector T-cell responses against tumour antigens are induced early during tumour development. Local dendritic cells (DCs) can acquire and process tumour proteins from lysed tumour cells, including mutated versions of normal proteins, and present peptides from these proteins to naïve T-cells in secondary lymphoid organs. This has the potential of generating potent tumour-specific effector T cells that could home to the tumour and facilitate selective tumour cell killing. However, tumours evolve diverse mechanisms of immune evasion and immunosuppression to prevent or restrain anti-tumour T-cell responses [3, 4]. This includes changing their antigen profile (to make them unrecognisable to effector T-cells [5, 6]), blocking T-cell recruitment [7, 8], and exploiting immunosuppressive leukocytes, such as regulatory T-cells (Tregs) and tumour-associated macrophages [9-11]. In addition, cancer cells and/or the tumour microenvironment (TME) can produce molecules that actively inhibit any tumour-specific T-cells that do manage to

enter the tumour [12-14]. All these processes are potential targets for therapeutic interventions that aim to induce, re-instate or enhance anti-tumour T cell responses. There have been several exciting recent successes with cancer immunotherapies: principal among these are antibodies targeting the 'immune checkpoint' proteins CTLA-4 or PD-1.

Enhancing anti-tumour T cell responses with anti-CTLA-4 antibodies.

Full activation of naïve T-cells results in clonal expansion and the development of effector functions. This requires positive signals from several membrane receptors. 'Signal one' comes from the T cell receptor (TCR) after it engages cognate antigen displayed on target cell MHC, but secondary positive signals (co-stimulation) are also essential, while further signals through cytokine receptors shape effector T-cell phenotype [15-18]. Co-stimulatory signals are principally delivered through CD28 receptors after they bind CD80 and CD86 (also known as B7.1 and B7.2, respectively), which are abundantly expressed on mature DCs. CTLA-4 also binds to CD80/86 with higher affinity than CD28 but it negatively regulates co-stimulation [19, 20]. CTLA-4 is transiently induced on activated T-cells, peaking 2-3 days after initial activation [19], and is strongly expressed by Treg: naturally occurring Treg (nTreg) are the major cell type constitutively expressing this molecule [9]. The receptor CTLA-4 is reported to transduce negative intracellular signals [21, 22] and enhance T cell motility [23, 24], but perhaps more significant is its ability to outcompete CD28 molecules for CD80/86 binding [19, 24, 25]; displace CD28 to distal regions of the immunological synapse [26, 27]; and strip CD80/86 from the surface of dendritic cells [28, 29]. These immunosuppressive activities prevent or restrain T-cell activation, and ensure that auto-reactive T-cells, or those that bind weakly to antigen, fail to become activated and instead enter a state of unresponsiveness (anergy).

The immunosuppressive properties of CTLA-4 are evident in *Ctla4*-deficient mice, which develop fatal lymphoproliferative disease and multi-organ failure due to unopposed T-cell activation and loss of immunological tolerance [30, 31]. These phenotypes are rescued by blocking or deleting CD80/86 or CD28. Moreover, germline heterozygous mutations in *CTLA4* in humans are linked to severe immune dysregulation [32, 33], and a *CTLA4* variant is associated with early onset Crohn's disease and autoimmunity [34]. Individuals with *CTLA4* mutations have defective Treg function, hyperactivated effector T cells, and reduced numbers of circulating B cells [32, 33].

It is well established that anti-CTLA-4 monoclonal antibodies can block the immunosuppressive properties of CTLA-4 and enhance anti-tumour T-cell responses in animal models [35, 36].

Blockade induces a reduction in Tregs and an increase in effector T-cells within the TME, and simultaneous blockade of CTLA-4 on these cells can synergise to enhance anti-tumour responses in animal models [37-43]. Anti-CTLA-4 antibodies can also bind Fcγ receptors (FcγRs) to mediate antibody-dependent cell-mediated cytotoxicity against CTLA-4⁺ Tregs, leading to their selective depletion [40-43]. This is largely dependent on the presence of atypical, FcγR-expressing macrophages in the tumour [40-43] and this mechanism of intra-tumoural Treg depletion has been identified in humans treated with ipilimumab [44].

The functional effects of anti-CTLA-4 antibodies on anti-tumour responses in a patient depend on the characteristics of the patient's tumour, the underlying TME, and the nature of any previous or concurrent therapies. Predicting responses is challenging and, given the profound immunological consequences of *Ctla4* deletion, or genetic variation in *CTLA4*, the potential side effects of administering anti-CTLA-4 antibodies may be significant. However the preclinical research and clinical trial data from CTLA4 blockade has provided a proof-of-principle and laid the groundwork for further targeted disruption of other immune checkpoints such as the PD-1 / PL-L1 axis.

Dismantling tumour defence by inhibiting PD-1 activity.

PD-1 is a surface receptor for the cognate ligands PD-L1 and PD-L2. It is expressed predominantly by activated T cells, but is also found on other leukocyte subsets, including activated B-cells, DCs, monocytes and NK cells [45-47]. PD-L1 can be found on activated T- and B-cells, DCs, macrophages and many tissue cells [47-50], while PD-L2 appears limited to DCs and macrophages and some stromal cells [47]. On effector T-cells, PD-1 ligation causes dephosphorylation of key signalling molecules that lie downstream of the TCR, thereby dampening TCR-mediated T-cell activation [51, 52]. It has also recently been identified that PD-1 / PD-L1 interactions trigger dephosphorylation of CD28 preferentially over the TCR, and is the primary mechanism of T cell suppression [53]. PD-1 also enhances T-cell motility to limit T-cell/DC interactions [54]. PD-L1 has also been reported to bind to CD80 and might, like CTLA-4, compete with CD28 [55]. Deletion of *Pd-1* leads to autoimmune disease [56, 57], but this develops later in life than the more severe, early onset disease in *Ctla4*^{-/-} mice [30, 31]. Expression of PD-L2 in lymphoid organs is thought to help maintain tolerance [51], while PD-L1, which is upregulated in response to interferons, particularly IFN-γ, protects tissues from excessive immune cell activity [48, 49]. This occurs during chronic viral infection when persistent viral antigen exposure causes T-cell exhaustion, a form of anergy [58, 59]. In this context,

blockade of PD-L1 by administration of anti-PD-L1 antibodies causes a resurgence of effector T-cell activity [60], predominantly through reactivation of the CD28 signalling pathway [61]. Thus, the physiological functions of the PD-1 pathway are to maintain T-cell tolerance and suppress effector T-cell responses in peripheral tissues.

Cancers can exploit the PD-1 pathway, upregulating PD-1 ligands to suppress T-cell-mediated cytotoxicity. Up-regulated PD-1 expression by tumour-infiltrating lymphocytes is associated with poor outcomes in many human cancers and correlates with an exhausted T-cell phenotype that impedes tumour immunity [62-67]. Early *in vivo* experiments demonstrated that myeloma cells were more effectively targeted when *Pd-1* was absent, and that anti-PD-L1 antibodies could suppress myeloma in wild-type mice [68]. In other mouse models, transplantation of *Pd-1*^{-/-} T cells [69] or administration of anti-PD-L1 antibodies [68, 69] induced regression of established tumours. PD-L1 expression by infiltrating myeloid cells has also been shown to impair anti-tumour T-cell immunity [72, 73], but interestingly this may be due in part to the induction and regulation of peripherally induced Treg subsets (iTreg) by the PD-L1-expressing myeloid cells [74]. Disruption of this process may represent an additional mechanism underpinning the enhanced anti-tumour immunity that can be induced by PD-1 blockade.

Translating efficacy from bench to bedside.

CTLA-4 and PD-1 provide critical but discrete mechanisms of physiological immunoregulation. A wealth of experimental data shows that antibodies blocking these checkpoints can enhance anti-tumour immune responses in animal models. Despite some concerns over potential toxicities, this drove the development of humanised monoclonal antibodies targeting these molecules. These novel immunotherapies are referred to as 'immune checkpoint inhibitors' (ICIs). These have now been licensed in a number of different tumour types (Figure 1), and are discussed briefly here.

Anti-CTLA-4: licensing ipilimumab for metastatic melanoma.

Ipilimumab (Bristol Myers Squibb), an anti-CTLA-4 antibody, was licensed for malignant melanoma in 2011 [73]. This followed a landmark phase III clinical trial involving around 600 patients with previously treated malignant melanoma [76] (Table 1). There were three treatment arms: ipilimumab plus gp100 vaccine, ipilimumab alone, or gp100 vaccine alone. The

gp100 vaccine targets a protein abundantly expressed by melanomas [77, 78]. The treatments containing ipilimumab conferred greatest median overall survival (OS): 10.0 months (ipilimumab/gp100) and 10.1 months (ipilimumab monotherapy) versus 6.4 months (gp100 vaccine alone). Severe immune-related adverse effects (IAEs) were reported in 10-15% of patients receiving ipilimumab, and were of longer duration in the ipilimumab/gp100 cohort [76]. Established protocols for managing immune-mediated toxicities were adopted from previous trials [79-81]. Subsequent analysis of data from 1,861 metastatic melanoma patients in 12 individual clinical trials of ipilimumab showed that OS at 3 years was 20% for previously treated patients and 26% for treatment-naive patients [82]. The survival curve plateaued at around 3 years, with evidence of long-term progression-free survival of up to 10 years in some patients.

PD-1 blockade moves into the clinic.

The safety and efficacy of pembrolizumab (Merck), a monoclonal antibody targeting PD-1, was demonstrated in patients with ipilimumab-refractory malignant melanoma. In an expansion cohort of a phase I trial, 173 patients were treated every 3 weeks with pembrolizumab [83]. Equivalent efficacy, as determined by overall response rates (ORR) [84], was observed at both dosing regimens (ORR=26%). Pembrolizumab was well tolerated: only 12% of patients developed drug-related grade 3 / 4 toxicities. Given the promising clinical responses, good safety profiles and absence of other effective therapies, pembrolizumab was licensed for ipilimumab-resistant advanced melanoma in 2014 [85].

In 2015, Robert and colleagues demonstrated significant improvements in progression-free survival, OS, response rates, and treatment related adverse events of pembrolizumab monotherapy compared with ipilimumab in advanced melanoma [86] (Table 1). A total of 834 patients were randomised to either pembrolizumab every 2 weeks, pembrolizumab every 3 weeks, or four cycles of ipilimumab every 3 weeks. The 12- and 24-month OS was significantly greater in the pembrolizumab groups, and progression-free survival at 6 months was 47.3%, 46.4% and 26.5%, respectively, with more durable responses seen in the pembrolizumab groups at 7.9 months [87]. Lower rates of significant immune-mediated toxicities were also seen in the pembrolizumab groups.

A phase I clinical trial of another anti-PD-1 monoclonal antibody, nivolumab (Bristol Myers Squibb), was conducted in 296 patients with melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC) or other selected treatment-refractory malignancies [88]. Melanoma

patients were treated every 2 weeks with increasing doses of 0.1-10mg/kg and showed overall objective response rates of 28%, with the highest response rate (41%) at a dose of 3mg/kg. Responses were durable in many responders. Grade 3/4 treatment related adverse events occurred in 14% of patients, with IAEs in 6%. Longer-term follow up of melanoma patients showed 1- and 2-year survival rates of 62% and 43% respectively, with an OS of 16.8 months [89]. Long-term safety evaluation was comparable to the original analysis, with 22% experiencing grade 3/4 treatment related adverse events and 5% having grade 3/4 IAEs. Toxicities were not cumulative and almost exclusively occurred in the first 6 months of therapy.

In an open-label, randomized, phase III study involving patients with ipilimumab-refractory melanoma, nivolumab was associated with a higher ORR than chemotherapy (32% versus 11%) [90]. Subsequently, nivolumab was compared with dacarbazine in patients with previously untreated metastatic melanoma without BRAF mutation [91]. Nivolumab gave superior 1-year survival (72% versus 42%), progression-free survival (5.1 versus 2.2 months), and ORRs (40% versus 13.9%). The survival benefit with nivolumab was observed across pre-specified subgroups, including those defined by PD-L1 status. Grade 3/4 drug-related adverse events occurred in 11.7% of nivolumab-treated patients and 17.6% of those receiving dacarbazine.

Combination regimens of ICIs in patients with advanced melanoma.

The distinct mechanisms of actions of anti-PD-1 and anti-CTLA-4 infer that their co-administration could have enhanced efficacy (Figure 2). The first phase I study combining two ICIs, nivolumab and ipilimumab, was undertaken in patients with malignant melanoma and used an initial dose-escalation trial design to identify safe doses of these drugs when used in combination regimens [92]. 1mg/kg nivolumab and 3mg/kg ipilimumab were the maximum doses associated with acceptable levels of adverse events. This regimen yielded objective responses in 21/52 patients (40%). Durable responses, ranging from 6.1 to 72.1 weeks, were ongoing in 19 patients at the time of publication. Impressively, 16 patients had tumour reduction $\geq 80\%$ at 12 weeks, including 5 with a complete response, although treatment-related grade 3/4 adverse events were reported in 53% of patients. Updated OS data was 82% and 75% for 1- and 2-year survival, respectively (Table 1) [93]. Thus, this preliminary trial data indicated that simultaneous targeting of PD-1 and CTLA-4 could be tolerated and result in durable responses.

The Checkmate 069 trial compared nivolumab plus ipilimumab, with ipilimumab monotherapy in patients with untreated malignant melanoma (Table 1). Greater objective responses were seen with combination therapy (61% versus 11% with ipilimumab alone), with complete responses in 22% of patients on combination therapy but none with ipilimumab alone [94]. 1- and 2-year OS was 73.4% and 63.8%, respectively, in the combination cohort, compared with 64.8% and 53.6% with ipilimumab alone [95]. Importantly, 2-year survival was not significantly affected by *BRAF* mutation or tumour PD-L1 expression status at diagnosis. A large subsequent phase III trial (Checkmate 067) compared nivolumab alone, ipilimumab alone, and nivolumab plus ipilimumab: median progression-free survival was 6.9 months, 2.9 months and 11.5 months, respectively [96]. Notably, in patients with PD-L1-negative tumours, progression-free survival was greater with combination therapy than either monotherapy. Furthermore, with a minimum follow-up of 36 months, the median overall survival has not been reached in the combination regimen arm and was 37.6 months in the nivolumab arm of the study compared with 19.9 months with ipilimumab monotherapy (HR = 0.55, $P < 0.001$ for combination versus ipilimumab; HR = 0.65, $P < 0.001$ for nivolumab versus ipilimumab). The overall survival at 3 years was 58%, 52% and 34% for the combination regimen, nivolumab, and ipilimumab monotherapy respectively. However, treatment-related grade 3 / 4 toxicities occurred in 59%, 21% and 28% of patients treated with the combination regimen, nivolumab, and ipilimumab respectively [97].

A phase II trial (Checkmate 064) has also revealed intriguing results of switching between nivolumab and ipilimumab [98]. Melanoma patients underwent induction with either nivolumab (3mg/kg every 2 weeks; six doses) and then ipilimumab (3mg/kg every 3 weeks; four doses), or the reverse sequence. This was followed by maintenance therapy with nivolumab (3mg/kg every 2 weeks) in both cohorts. Greater efficacy was observed in the nivolumab followed by ipilimumab cohort, with significantly greater 1-year OS than the reverse sequence (Table 1). As expected from previous combination trials, the frequency of IAEs was relatively high (43-50%), although this was not affected by the order of drug administration.

Collectively, these trials have allowed ICIs, either alone or in combination, to herald in a new era of immunotherapy for the treatment of malignant melanoma. Impressive durable responses have led to unprecedented improvements for some patients with metastatic disease. Administering ICIs in combination with other therapeutics will no doubt further expand their use in cancer patients.

New therapeutic approaches for non-small-cell lung cancer.

Anti-CTLA-4 therapy has been trialled in patients with NSCLC but promising outcomes akin to those seen in patients with melanoma have not been forthcoming. One initial trial used tremelimumab, an anti-CTLA-4 antibody, but it showed minimal efficacy and a significant side effect burden [99], and, when used in combination with chemotherapy, anti-CTLA-4 antibodies have consistently demonstrated only modest improvements in responses in NSCLC patients [100, 101]. However, antibodies targeting the PD-1/PD-L1 axis have shown greater efficacy and marked reductions in side effects so have largely replaced anti-CTLA-4 antibodies as the ICI of choice in NSCLC.

In 2015, nivolumab received FDA approval for use in patients with advanced squamous-cell NSCLC who progressed during or after, platinum chemotherapy (Table 2) [85]. This followed a phase III trial (CheckMate-017) of nivolumab compared with docetaxel chemotherapy in patients with progressive disease following first-line chemotherapy [102]. Median OS was 9.2 months in the nivolumab cohort, compared with 6.0 months in those receiving docetaxel. At 12 months, OS was 42% with nivolumab, and 24% with docetaxel. Pre-treatment tumour PD-L1 expression was not predictive of efficacy. A similar phase III trial (CheckMate-057) demonstrated considerable improvements in survival for patients with advanced non-squamous NSCLC treated with nivolumab compared to those receiving docetaxel [103]. OS at 12 and 18 months was higher for patients on nivolumab compared with those on docetaxel. An additional phase II trial (CheckMate-063) supports the survival benefit of nivolumab, reporting a 1-year OS of 40.8% [104]. Similarly, compared with docetaxel, pembrolizumab showed greater efficacy than docetaxel in advanced NSCLC in a phase II/III trial (KEYNOTE-010) [105, 106]. Patients with $\geq 1\%$ PD-L1 expression on the tumour received 2mg/kg pembrolizumab, 10mg/kg pembrolizumab, or docetaxel, resulting in median OS of 10.4, 12.7 or 8.5 months, respectively. Greater efficacy was seen in patients with high tumour PD-L1 expression. These results echo findings from a similar phase I study (KEYNOTE-001) investigating pembrolizumab in NSCLC [107], while a phase III trial (KEYNOTE-024) demonstrated survival benefits, durable responses, increased response rates and reduced treatment-related adverse events with pembrolizumab compared with platinum-based chemotherapy in previously untreated patients with $\geq 50\%$ tumoural PD-L1 expression [108]. This has led to pembrolizumab being licensed for treatment of naïve metastatic NSCLC with $\geq 50\%$ PD-L1 expression [83]. In contrast, nivolumab did not improve progression-free or overall survival compared with chemotherapy in patients (n=423) with previously untreated stage IV or recurrent NSCLC and with a PD-1 expression of 5% or more [109]. This suggests that robust predictive markers are required to optimally select patients for anti-PD-1 therapy, and

that the sequence of administration with other standard therapies may also be relevant for optimal treatment strategies.

In the phase II POPLAR trial, atezolizumab (Genentech), an antibody targeting the PD-L1 rather than PD-1, showed improved OS for NSCLC patients who had progressed following platinum chemotherapy [110]. This study included prospective evaluation of tumour PD-L1 expression, and used immune gene expression to define and quantify effector T-cell activity within the TME. It was clear that efficacy was closely related to both PD-L1 expression and effector T-cell abundance in the tumour. Future studies should consider incorporating this pre-treatment analysis of the presence of active tumour-infiltrating effector T-cells that may be a predictive marker of ICI efficacy. The clinical outcomes of POPLAR were reiterated in OAK, a phase III clinical trial demonstrating improved median OS with atezolizumab versus docetaxel (13.8 versus 9.6 months) in NSCLC patients progressing on platinum chemotherapy, although improvement in OS was seen regardless of tumour PD-L1 expression [111, 112]. As a result of these trials, in 2016 the FDA approved atezolizumab for the treatment of metastatic NSCLC that has progressed on platinum chemotherapy [85].

Significantly, PD-L1/PD-1 inhibitors not only improve OS but they are also associated with fewer treatment-related adverse events (\geq grade 3) than chemotherapy [102, 103, 105, 108-111]. Moreover, they may have broad usage: although strongest responses were seen in patients with high tumour PD-L1 expression, they also showed similar, if not greater, efficacy than chemotherapy in patients with very low tumour PD-L1 expression [102-107, 110, 111]. It has not yet been possible to accurately stratify patient responses based on PD-L1 expression, although this typically involves the analysis of a single pre-treatment tumour biopsy, sometimes taken long before starting checkpoint blockade therapy. In the Checkmate-063 trial, for example, there was a median of 1.3 years between biopsy and commencing nivolumab [104]. Thus, more detailed studies are required to explore the prognostic value of tumour PD-L1 expression, and ideally analysis of effector T-cell abundance and phenotype should also be included.

ICIs offer new hope for treating NSCLC, which historically has poor survival outcomes in patients with metastatic disease, and they have become standard second-line therapies in NSCLC patients. They are also being used as first-line treatments, particularly for patients with PD-L1-expressing tumours, although optimal ICI treatment strategies, with or without chemotherapy, still need to be more precisely defined in this context [113]. Trials using a combination of anti-CTLA4 and anti-PD-L1 antibodies have begun in NSCLC patients, with two phase I studies

demonstrating safety profiles comparable to those seen in melanoma patients (Table 2) [114, 115]. The results of on-going phase II/III trials are eagerly anticipated [116-118]. Other studies have focused on including ICIs into treatment strategies either in combination or sequentially after other existing therapies in NSCLC. For example, patients (n=713) with locally advanced unresectable NSCLC were randomly assigned (2:1) to receive consolidation therapy with either the anti-PDL-1 antibody durvalumab, or placebo every 2 weeks for up to 12 months after definitive chemoradiotherapy (chemotherapy with concurrent radiotherapy). Patients treated with durvalumab had a significantly improved progression-free survival (16.8 months versus 5.6 months; HR = 0.52, P<0.001) and objective response rates 28.4% versus 16%; P<0.001) [119].

ICIs show efficacy in other cancers.

ICIs have been, or are being, investigated in clinical trials across a broad range of other cancers in the hope that responses seen in patients with melanoma or NSCLC can be reproduced in patients with other tumour types.

PD-L1 expression has long been known to be associated with tumour aggressiveness and poorer outcomes in patients with **Renal Cell Carcinoma (RCC)** [120, 121]. Nivolumab demonstrated efficacy in a phase II trial of 168 patients with metastatic RCC [122]. They received 0.2, 2 or 10mg/kg of nivolumab: median OS was 18.2, 25.5 or 24.7 months, respectively. In a subsequent phase III study, patients that had previously received anti-angiogenic therapy had a median OS of 25.0 months on nivolumab compared with 19.6 months on everolimus (an mTOR inhibitor recommended after failed anti-angiogenic therapy) [123]. Nivolumab was subsequently approved for use in patients with advanced RCC after failing anti-angiogenic therapy [85]. Interestingly, high tumour PD-L1 expression was not associated with improved responses to therapy in this study: median OS in patients with PD-L1 expression $\geq 1\%$ was 21.6 and 18.8 months (nivolumab and everolimus, respectively), but 27.4 versus 21.2 months in patients with $\leq 1\%$ tumour PD-L1 expression. This emphasises the need to carefully consider the suitability of using PD-L1 expression alone to predict responses.

Following two clinical trials [124, 125], atezolizumab, and more recently nivolumab, have been granted FDA approval for **bladder cancer** patients with disease progression within 12 months of treatment with platinum-containing chemotherapy [85]. The phase II trial using atezolizumab improved objective response rates compared with a historical control [124]. Approximately 15% of patients responded, and in this case, PD-L1 expression on tumour-associated immune cells

correlated with objective responses. Ongoing responses in 84% of responders demonstrate excellent treatment durability, and for a small fraction (5%) a complete response was observed. This trial attempted to define features of the TME associated with responses. In addition to PD-L1 expression, it determined CD8+ T-cell infiltration, mutational load, and molecular subtype. Several 'immune cell' genes were associated with complete and partial responses to atezolizumab, including the IFN- γ -inducible genes *CXCL9* and *CXCL10*, which encode chemokines that direct leukocyte and CD8⁺ T-cell homing. Mutational load was also significantly higher in responders than non-responders (12.4 versus 6.4 mutations per Mb). High mutational load has also been correlated with responses to anti-CTLA-4 in malignant melanoma [126], and may predict better survival in melanoma patients treated with anti-PD1 therapy [127]. This is most likely because increased mutation will increase the generation of neoantigens recognizable by T-cells. Thus, in addition to characterizing PD-L1 expression and the immune cell infiltrate, efforts to predict ICI responses should take into account the mutational landscape of the tumour.

Tumours with mismatch-repair (MMR) defects contain a large number of somatic mutations so may be particularly sensitive to ICIs. Indeed, in a recent phase II trial pembrolizumab was administered every two weeks to patients with MMR-deficient **colorectal cancers** (n=11), MMR-proficient colorectal cancers (n=21), or MMR-deficient cancers that were not colorectal (n=9) [128]. The objective response rate and progression-free survival rate at 20 weeks were 40% and 78% for MMR-deficient colorectal cancers; 71% and 67% for non-colorectal MMR-deficient cancers; and 0% and 11% for MMR-proficient colorectal cancers. This apparent sensitivity of MMR-deficient tumours supports the rationale of combining DNA repair inhibitors with ICIs in clinical trials, and a Phase I/II study combining the poly ADP Ribose Polymerase (PARP) inhibitor, olaparib, with durvalumab in patients with selected advanced malignancies is ongoing [129].

PD-1 blockade has shown positive outcomes in **classical Hodgkin's lymphoma**. Nivolumab and pembrolizumab are now FDA-approved for treatment of patients who have relapsed after other therapies. Two clinical trials have reported ORRs of 65% and 87%, with complete response rates in 16% and 17% of patients [130, 131]. Nivolumab and pembrolizumab are also approved for use in patients with recurrent or metastatic **squamous cell carcinoma of the head and neck (SCCHN)** whose disease has progressed after administration of platinum-based therapeutics [85]. Pembrolizumab treatment gave a clinically significant ORR, and durable responses were evident in some patients [132], while nivolumab improved overall survival compared to standard single-agent therapy (methotrexate, docetaxel or cetuximab) [133]. However, in a phase III study of

pembrolizumab versus standard of care in patients with recurrent or metastatic SCCHN, pembrolizumab yielded a 19% reduction in the risk of death compared with standard of care, but this did not meet the pre-specified efficacy boundary, although it is possible that subsequent immunotherapy use in the standard of care arm may have confounded the overall survival analysis [134]. Nonetheless, greater differences in overall survival, progression-free survival, and objective response rates were seen in patients with PD-1-expressing tumours [134].

Based on a phase II clinical trial involving 88 patients, avelumab (Merck – Pfizer), a PD-L1 blocking antibody, received FDA approval for use in patients with metastatic **Merkel cell carcinoma** [85, 135]. This is the first ever drug approved for this rare skin cancer, in which Merkel cell polyomavirus infection is a major aetiological factor [136]. Nearly a third of patients showed objective responses, with eight complete responses reported: five grade 3 treatment-related adverse events were noted [135]. Pembrolizumab has also been trialled on 26 patients with this disease, with an ORR of 56% being reported, including four complete responses [137].

In a large phase III trial involving 1,132 patients with extensive late-stage **small-cell lung cancer (SCLC)**, ipilimumab with chemotherapy versus placebo with chemotherapy demonstrated no significant difference in OS [138]. A previous phase I/II trial had also given disappointing results in SCLC, with no survival advantage for patients receiving ipilimumab [139]. However, nivolumab, either alone or in combination with ipilimumab, showed anti-tumour activity with durable responses and manageable safety profiles in previously treated patients with SCLC [140]. Patients were administered nivolumab (3mg/kg); nivolumab (1mg/kg) plus ipilimumab (3mg/kg); or nivolumab (3mg/kg) plus ipilimumab (1mg/kg). Objective responses were seen in 10%, 23% and 19% patients, respectively. Pembrolizumab is currently under investigation in patients with PD-L1+ ($\geq 1\%$ expression) SCLC, who have progressed during or after platinum-based chemotherapy [141]. Initial results indicate good tolerability and, while the data are preliminary, the initial report shows that 25% of SCLC patients developed a partial response.

A phase III trial compared ipilimumab against placebo, following radiation, in patients with metastatic castration-resistant **prostate cancer** that progressed on docetaxel chemotherapy [142]. They reported no significant improvement in OS: median OS was 11.2 months for ipilimumab and 10.0 months for placebo. However, subgroup analysis revealed improved OS outcomes for patients with better prognostic factors. This is perhaps unsurprising, as it is now established that immunotherapies often take longer to show measurable efficacy [143]. Final results from a completed Phase III trial comparing placebo with ipilimumab in minimally

symptomatic, previously untreated patients with metastatic castration-resistant prostate cancer should reveal whether there is a role for ICIs in this malignancy [144]. Finally, promising responses have also been observed with anti-PD-1 antibody treatment in patients with refractory gastric cancer [145, 146] or hepatocellular carcinoma [147]: results of randomized trials are eagerly awaited.

Thus, in addition to melanoma and NSCLC, ICI monotherapies, particularly those targeting the PD-1 pathway, are yielding positive outcomes in a range of metastatic cancers. Toxicities are evident and need to be managed, and the long-term health implications of ICI monotherapy have yet to be determined. This might be significant, given the improvements in patient survival seen with ICIs, though the issue of resistance to ICIs raises the challenge of how to treat cancers which fail multiple therapies.

Future prospects for ICIs in combination therapies.

Clinical trial data have justifiably generated considerable excitement about the effectiveness of ICIs. In many cases, responses are durable, perhaps even curative, possibly because they release systemic personalized memory T-cell responses against multiple patient-specific tumour antigens. However, only subsets of patients respond to ICI monotherapy. Combining ICIs can improve outcomes, and further ICI combination trials, with careful side effect monitoring, are certainly merited. There are also a large number of ongoing clinical trials exploring ICIs in combination with other treatment modalities, such as radiotherapy, chemotherapy, or molecular targeted therapies [148]. The administration of ICIs after radiotherapy attempts to augment the 'abscopal effect', where localized radiation-induced tumour cell death can deliver anti-tumour immune responses against distant tumour deposits (Figure 1) [149-154]. ICIs even show activity against tumours classically viewed as poorly immunogenic, such as pancreatic adenocarcinoma and glioblastoma, with efforts aimed at administering ICIs while either modifying the TME, up-regulating neoantigen abundance [155] or, in glioblastoma, potentiating immune responses using adenovirus [156]. Modulating the chemokine composition of the TME [157], or blocking chemokine receptors [158], can also enhance ICI efficacy in animal models, and these approaches may translate to humans. Preliminary data in animal tumour models has shown that depletion of Tregs via modified anti-CD25 antibody plus anti-PD-1 antibody can induce complete regression of established tumours [159]. In short, combination therapies have the potential to further improve the activity and scope of ICIs, leading to the induction of durable effector T-cell responses in more patients, and across a greater range of malignancies.

Integrating ICIs into precision oncology.

The future of oncology will undoubtedly involve a precision approach to patient care, with treatment tailored to an individual's disease to maximise efficacy and ameliorate side effects as far as possible. Numerous factors determine a patient's response to ICIs. These include, but are not limited to, the distribution of the target immune checkpoint protein; the immune cell context within the tumour; the availability, immunogenicity and frequency of tumour antigens; the pharmacodynamics and pharmacokinetics of the ICI; and the amenability of the TME for effective drug delivery [160]. The analysis of these factors must be incorporated into the design of future clinical trials so that combinations of biomarkers that predict response to ICI immunotherapy can be identified and exploited. It will also be important to further clarify the reciprocal relationship between tumour cells and the TME in the context of ICI therapies, particularly if they are to be implemented across a range of different malignancies. Clinical trials have evolved from when tumours were classified according to histological observations, and comprehensive molecular, cellular and genetic phenotyping is now possible. Genomic and transcriptomic analysis of pre-treatment melanoma has identified a transcriptional signature associated with innate resistance to anti-PD1 therapy, and demonstrated that mutations in the DNA repair gene *BRCA2* are enriched in patients that do respond [161]. The analysis of serial tumour biopsies taken before, during and after ICI therapy will further enhance understanding of how anti-tumour responses are induced by ICIs, and how tumours adapt to evade or limit these responses. Interestingly, one study has identified mutations in melanoma cells in patients whose disease progressed after initially responding to PD-1 blockade [162], and at least one trial is underway that aims to understand the selection pressures and evolutionary changes that ICIs impose on tumour cells [163].

Concluding remarks.

The development and application of ICIs has been a major advance in the treatment of cancer, dramatically rekindling academic, clinical and commercial interest in anti-cancer immunotherapies. As monotherapies, they show considerable promise and remarkable responses have been seen in some patients. However it is clear that there is improved efficacy when these ICIs are used as part of a concerted therapeutic approach for management of malignant disease. The key issue to be resolved is generation of sufficient evaluable data from combinatorial trials to define effective parameters for treatment. Results from current trials where ICIs are combined with chemotherapy, radiotherapy or with other immunotherapies are

starting to demonstrate which malignancies are particularly susceptible to immune reactivation. These studies are also providing clear evidence that though ICIs have produced dramatic improvements in some patients, they are not necessarily sufficient to mediate long-term remission or cure in most. Identification and validation of suitable prognostic markers in patient cohorts will also help to stratify treatment modalities and target therapy to those patients most likely to respond. The corollary to this is that suitable prognostic criteria could also minimize the IAEs associated with ICI treatment and immune reactivation [164]. The management of side effects and the evolution of resistance are ongoing concerns, but further advances are anticipated as these new medicines are incorporated into combination therapies and integrated into precision oncology. Progress is likely to be swift given the current explosion in clinical trials of ICIs and the rapidly expanding number of preclinical studies involving these drugs will no doubt stimulate further clinical applications. The range of new ICIs becoming available, and the novel checkpoint targets being identified and characterised in preclinical studies, means that the resistance or relapse seen in some patients could be reversed by using alternative checkpoint inhibitors. There is also a significant new approach to tumour immunotherapy with the recent FDA approval for autologous gene-modified chimeric antigen receptor (CAR) T cell therapy. This cell therapy (Kymriah, Novartis) targets CD19 in B cell acute lymphocytic leukaemia and has shown significant efficacy [165]. There are several other CAR-T cell therapies in development, and combination therapy with ICIs is already planned, offering the potential for even greater benefits. ICIs are important new weapons in the oncologist's arsenal and exciting times lie ahead in the field of cancer immunotherapy.

Acknowledgements.

The authors would like to thank Alison Schroeer of Schroeer Scientific Illustration for assistance with the preparation of figure 2.

Competing Interests

The authors confirm that they have no competing financial interests or activities.

References.

1. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol* 2013: 14(10); 1014-22.
2. Speiser DE, Ho PC, Verdeil G. Regulatory circuits of T cell function in cancer. *Nat Rev Immunol* 2016: 16(10); 599-611.
3. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. *Immunity* 2004: 21(2); 137-48.
4. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. *Oncogene* 2008: 27(28); 3889-900.
5. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. *J Leukoc Biol* 2002: 71(6); 907-920.
6. Swann JB, Smyth MJ. Immune surveillance of tumors. *J Clin Invest* 2007: 117(5); 1137-46.
7. Bouzin C, Brouet A, De Vriese J, Dewever J, Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. *J Immunol* 2007: 178(3); 1505-11.
8. Buckanovich RJ et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. *Nat Med* 2008: 14(1); 28-36.
9. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. *Clin Exp Immunol* 2013: 171(1); 36-45.
10. Facciabene A, Motz GT, Coukos G. T Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis. *Cancer Res* 2012: 72(9); 2162-71.
11. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. *Cell* 2010: 140(6); 883-99.

12. Dong H et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med* 2002: 8(8); 793-800.
13. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. *Nat Rev Immunol* 2008: 8(6); 467-77.
14. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012: 12(4); 252-64.
15. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. *Nature* 1992: 356(6370); 607-9.
16. McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 co-stimulation in activation and differentiation of CD4⁺ and CD8⁺ T cells. *Immunol Rev* 1998: 165; 231-47.
17. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. *Nat Rev Immunol* 2003: 3(12); 939-51.
18. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol* 2013: 13(4); 227-42.
19. Krummel MF, Allison JP. CD28 and CTLA-4 Have Opposing Effects on the Response of T cells to Stimulation. *J Exp Med* 1995: 182; 459-465.
20. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. *Immunity* 1994: 1(5); 405-13.
21. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. *Nat Rev Immunol* 2001: 1(3); 220-8.
22. Lee KM et al. Molecular basis of T cell inactivation by CTLA-4. *Science* 1998: 282(5397); 2263-6.
23. Schneider H et al. Reversal of the TCR stop signal by CTLA-4. *Science* 2006: 313(5795); 1972-5.
24. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. *Nat Rev Immunol* 2011: 11(12); 852-63.
25. Greene JL, Leytze GM, Emswiler J, Peach R, Bajorath J, Cosand W, Linsley PS. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. *J Biol Chem* 1996: 271(43); 26762-71.

26. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. *Immunity* 2002; 16(1); 23-35.
27. Yokosuka T et al. Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation. *Immunity* 2010; 33(3); 326-39.
28. Qureshi OS et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. *Science* 2011; 332(6029); 600-3.
29. Walker LS, Sansom DM. Confusing signals: Recent progress in CTLA-4 biology. *Trends Immunol* 2015; 36(2); 63-70.
30. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity* 1995; 3(5); 541-7.
31. Waterhouse P et al. Lymphoproliferative disorders with early lethality in mice deficient in CtlA-4. *Science* 1995; 270(5238); 985-8.
32. Kuehn HS et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. *Science* 2014; 345(6204); 1623-7.
33. Schubert D et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. *Nat Med* 2014; 20(12); 1410-6.
34. Zeissig S et al. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. *Gut* 2015; 64(12); 1889-97.
35. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. *Science* 1996; 271(5256); 1734-6.
36. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. *Cancer Res* 2000; 60(9); 2444-8.
37. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. *Cancer Immunol Res* 2013; 1(1); 32-42.
38. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. *J Clin Invest* 2006; 116(7); 1935-45.
39. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. *J Exp Med* 2009; 206(8); 1717-25.

40. Simpson TR et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. *J Exp Med* 2013; 210(9); 1695-710.
41. Bulliard Y et al. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. *J Exp Med* 2013; 210(9); 1685-93.
42. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating Fc γ Rs, leading to antitumor efficacy. *Immunol Cell Biol* 2014; 92(6); 475-80.
43. Śledzińska A, Menger L, Bergerhoff K, Peggs KS, Quezada SA. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. *Mol Oncol* 2015; 9(10); 1936-65.
44. Romano E et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. *Proc Natl Acad Sci* 2015; 112(19); 6140-5.
45. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J* 1992; 11(11); 3887-95.
46. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. *Int Immunol* 1996; 8(5); 765-72.
47. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol* 2008; 26; 677-704.
48. Yamazaki T, Akiba H, Iwai H et al. Expression of programmed death 1 ligands by murine T cells and APC. *J Immunol* 2002; 169(10); 5538-45.
49. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, Leonard JP. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. *Microcirculation* 2002; 9(2); 133-45.
50. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. *Cancer Med* 2013; 2(5); 662-673.
51. Latchman Y et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. *Nature Immunol* 2001; 2(3); 261–268.

52. Freeman GJ et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med* 2000; 192(7); 1027–34.
53. Hui E et al. T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition *Science* 2017; 355(6332); 1428-33.
54. Fife BT et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. *Nat Immunol* 2009; 10(11); 1185-92.
55. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. *Immunity* 2007; 27(1); 111-22.
56. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. *Immunity* 1999; 11(2); 141-51.
57. Nishimura H et al. Autoimmune dilated cardiomyopathy in PD-1 receptor deficient mice. *Science* 2001; 291(5502); 319–322.
58. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. *J Exp Med* 1998; 188(12); 2205-13.
59. Gallimore A, Glithero A, Godkin A, Tissot AC, Plückthun A, Elliott T, Hengartner H, Zinkernagel R. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. *J Exp Med* 1998; 187(9); 1383-93.
60. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* 2006; 439(7077); 682-7.
61. Kamphorst OA et al Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent *Science* 2017; 355(6332); 1423-27.
62. Thompson RH et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. *Proc Natl Acad Sci USA* 2004; 101(49); 17174-9.
63. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. *Clin Cancer Res* 2007; 13(6); 1757-61.

64. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. *Blood* 2009; 114(8); 1537-44.
65. Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. *Cell Mol Immunol* 2010; 7(5); 289-95.
66. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. *Cancer* 2010; 116(7); 1757-66.
67. Shi F et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. *Int J Cancer* 2011; 128(4); 887-96.
68. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. *Proc Natl Acad Sci USA* 2002; 99(19); 12293-7.
69. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. *Cancer Res* 2004; 63(3); 1140-5.
70. Strome SE et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. *Cancer Res* 2003; 63(19); 6501-5.
71. Hirano F et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. *Cancer Res* 2005; 65(3); 1089-96.
72. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. *J Exp Med* 2009; 206(6); 1327-37.
73. Curiel TJ et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. *Nat Med* 2003; 9(5); 562-7.
74. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. *J Exp Med* 2009; 206(13); 3015-29.
75. FDA.gov. 2011 Notifications. <http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm381453.htm> (Accessed: 13/10/2017).

76. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010; 363(8); 711-23.
77. Rosenberg SA et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nat Med* 1998; 4(3); 321-7.
78. Smith FO et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. *Clin Cancer Res* 2008; 14(17); 5610-18.
79. Weber J et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. *Clin Cancer Res* 2009; 15(17); 5591-8.
80. Wolchok JD et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncol* 2010; 11(2); 155-64.
81. O'Day SJ et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. *Ann Oncol* 2010; 21(8); 1712-7.
82. Schadendorf D et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. *J Clin Oncol* 2015; 33(17); 1889-94.
83. Robert C et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet* 2014; 384(9948); 1109-17.
84. Eisenhauer EA et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009; 45(2); 228-47.
85. FDA.gov. Hematology/Oncology (Cancer) Approvals & Safety Notifications. <http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm> (Accessed: 13/10/2017).
86. Robert C et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N Engl J Med* 2015; 372(26); 2521-32.
87. Schachter J et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. *J Clin Oncol* 2016; 34; (suppl; abstr 9504).

88. Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012; 366(26); 2443-54.
89. Topalian SL et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. *J Clin Oncol* 2014; 32(10); 1020-30.
90. Weber JS et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma with prior anti-CTLA-4 therapy. *European Society for Medical Oncology 2014 Congress* 2014.
91. Robert C et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med* 2015; 372(4); 320-30.
92. Wolchok JD et al. Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* 2013; 369(2); 122-33.
93. Sznol M et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). *J Clin Oncol* 2014; 32; Suppl:9003-9003.
94. Postow MA et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N Engl J Med* 2015; 372(21); 2006-17.
95. Hodi FS et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncol* 2016; 17(11); 1558-68.
96. Larkin J et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* 2015; 373(1); 23-43.
97. Wolchok JD et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *New Engl J Med* 2017; 377(14); 1345-56.
98. Weber JS et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. *Lancet Oncol* 2016; 17(7); 943-55.
99. Zatloukal P et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 2009; 27:abstr 8071.
100. Lynch TJ et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. *J Clin Oncol* 2012; 30(17); 2046-2054.

101. Govindan R et al. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. *J Clin Oncol* 2017; 35(30); 3449-57.
102. Brahmer J et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med* 2015; 373(2); 123-35.
103. Borghaei H et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med* 2015; 373(17); 1627-39.
104. Rizvi NA et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. *Lancet Oncol* 2015; 16(3); 257-65.
105. Herbst RS et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016; 387(10027); 1540-50.
106. Herbst RS et al. Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1-expressing NSCLC: Updated outcomes of KEYNOTE-010. *Ann Oncol* 2016; 27(suppl 6).
107. Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med* 2015; 372(21); 2018-28.
108. Reck M et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 2016; 375(19); 1823-33.
109. Carbone DP, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. *New Engl J Med* 2017; 376(25); 2415-2426.
110. Fehrenbacher L et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet* 2016; 387(10030); 1837-46.
111. Rittmeyer A et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet* 2017; 389(10066); 255-65.
112. Barles F et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. *Ann Oncol* 2016; 27(Supplement 6); vi552-vi587.
113. Remon J et al. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. *Lung Cancer* 2017; 106; 70-75.
114. Antonia S et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-

- small cell lung cancer: a multicentre, phase 1b study. *Lancet Oncol* 2016; 17(3); 299-308.
115. Hellmann MD et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. *Lancet Oncol* 2017; 18(1); 31-41.
116. A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC). ClinicalTrials.gov. <https://clinicaltrials.gov/show/NCT02352948> (Accessed: 13/10/2017).
117. Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC). ClinicalTrials.gov. <https://clinicaltrials.gov/show/NCT02453282> (Accessed: 13/10/2017).
118. Study of 1st Line Therapy Study of Durvalumab With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). (NEPTUNE). ClinicalTrials.gov. <https://clinicaltrials.gov/show/NCT02542293> (Accessed: 13/10/2017).
119. Antonia SJ, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *New Engl J Med* 2017; doi:10.1056/NEJMoa1709937.
120. Thompson RH et al Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. *Proc Natl Acad Sci* 2004; 101(49); 17174-9.
121. Thompson RH et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. *Cancer Res* 2006; 66(7); 3381-5.
122. Motzer RJ et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. *J Clin Oncol* 2015; 33(13); 1430-7.
123. Motzer RJ et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2015; 373(19); 1803-13.
124. Rosenberg JE et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet* 2016; 387(10031); 1909-20.
125. Sharma P et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. *Lancet Oncol* 2016; 17(11); 1590-98.
126. Snyder A et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med* 2014; 371(23); 2189-99.

127. Hugo W et al. Genomic and Transcriptomic Response to Anti-PD-1 Therapy in Metastatic Melanoma. *Cell* 2016: 165(1); 35-44.
128. Le DT et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med* 2015: 372(26); 2509-20.
129. Domchek S, et al. MEDIOLA: A phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients with advanced solid tumours. *Ann Oncol* 2016: suppl 6; 1103TiP
130. Ansell SM et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. *N Engl J Med* 2015: 374(4); 311-19.
131. Armand P et al. Programmed Death-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. *J Clin Oncol* 2016: 34(31); 373-39.
132. Chow LQ et al. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. *J Clin Oncol* 2016: 34(32); 3838-45.
133. Ferris RL et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med* 2016: 375(19); 1856-67.
134. Cohen EE, et al. Pembrolizumab versus standard of care for recurrent or metastatic head and neck squamous cell carcinoma: Phase 3 KEYNOTE-040 trial. *Ann Oncol* 2017: 28 (suppl 5) 628, LBA45.
135. Kaufman HL et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. *Lancet Oncol* 2016: 17(10); 1374-85.
136. Liu W, MacDonald M, You J. Merkel cell polyomavirus infection and Merkel cell carcinoma. *Curr Opin Virol* 2016: 20; 20-27.
137. Nghiem PT et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. *N Engl J Med* 2016: 374(26); 2542-52.
138. Reck M et al. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. *J Clin Oncol* 2016: 34(31); 3740-48.
139. Reck M et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. *Ann Oncol* 2013: 24(1); 75-83.

140. Antonia SJ et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol* 2016; 17(7); 883-95
141. Ott PA et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. *J Clin Oncol* 2015; 33; (suppl; abstr 7502).
142. Kwon ED et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2014; 15(7); 700-12.
143. Wolchok JD et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res* 2009; 15(23); 7412-20.
144. Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer. ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT01057810> (Accessed 14/04/2017).
145. Muro K et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. *Lancet Oncol* 2016; 17(6); 717-26.
146. Le DT et al. Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. *J Clin Oncol* 2016; 34; (suppl4S; abstr 6).
147. El-Khoueiry AB et al. Phase I/II safety and antitumour activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. *J Clin Oncol* 2015; 33; (suppl; abstr LBA101).
148. ClinicalTrials.gov
<https://clinicaltrials.gov/ct2/results?term=checkpoint+inhibitors&Search=Search>
(Accessed: 13/10/2017).
149. Twyman-Saint Victor C et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature* 2015; 520(7547); 373-7.
150. Postow MA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. *N Engl J Med* 2012; 366(10); 925-31.
151. Schoenfeld JD et al. Ipilimumab and cranial radiation in metastatic melanoma patients: a case series and review. *J Immunother Cancer* 2015; 3:50.

152. Simone CB, Burri SH, Heinzerling JH. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. *Transl Lung Cancer Res* 2015; 4(5); 545-52.
153. Palma DA, Louie AV, Rodrigues GB. New Strategies in Stereotactic Radiotherapy for Oligometastases. *Clin Cancer Res* 2015; 21(23); 5198-204.
154. Okwan-Duodu D1, Pollack BP, Lawson D, Khan MK. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. *Am J Clin Oncol* 2015; 38(1); 119-25.
155. Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer Patients (CheckPAC). ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT02866383?term=pancreas+AND+ipilimumab&rank=5>. (Accessed: 13/10/2017).
156. Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE). ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT02798406?term=checkpoint+inhibitors&rank=5>. (Accessed: 20/08/2016).
157. Peng D et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. *Nature* 2015; 527(7577); 249-53.
158. Steele CW et al. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. *Cancer Cell* 2016; 29(6); 832-45.
159. Vargas et al. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. *Immunity*. 2017; 46(4); 577-586.
160. Sharma P, Allison JP. The future of immune checkpoint therapy. *Science* 2015; 348 (6230); 56-61.
161. Hugo W et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. *Cell* 2016; 165(1); 35-44.
162. Zaretsky JM et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. *N Engl J Med* 2016; 375(9); 819-29.
163. Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies (SPECIAL). ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT02724488?term=checkpoint+inhibitors&rank=1>. (Accessed: 20/08/2016).

164. Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy *J Hematol Oncol* 2016; 9:47
165. Khalil D, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. *Nature Rev Clin Oncol* 2016; 13; 273–90.

Accepted Article

Figure 1: History of Checkpoint Inhibitors: Key Milestones

Timeline showing when checkpoint inhibitors were approved for the treatment of specific cancers in the USA, Europe and Japan. Tumour type is indicated by the colour of each ICI depicted in the figure, according to the key in the top left.

Abbreviations: 1L, first line; 2L, second line; NSCLC, non-small cell lung cancer; NSQ, nonsquamous; PD-L1, programmed death ligand 1; RCC, renal cell carcinoma; R/M, recurrent/metastatic; SCCHN, squamous cell carcinoma of the head and neck; SQ, squamous.

¹ U.S. Food and Drug Administration. <http://www.fda.gov>. Accessed November 11, 2016. ² European Medicines Agency. <http://www.ema.europa.eu>. Accessed November 11, 2016. ³ ONO Pharmaceutical Co., Ltd. [press release] July 4, 2014. ⁴ ONO Pharmaceutical Co, Ltd. [press release]. March 23, 2015. ⁵ ONO Pharmaceutical Co, Ltd. [press release]. December 17, 2015. ⁶ Merck [press release]. June 27, 2016. Accessed August 8, 2016. ⁷ Bristol-Myers Squibb Company [press release]. November 22, 2016. ⁸ Merck [press release]. December 19, 2016.

Figure 2: ICI blockade reverses tumour-mediated immune suppression

A) Established tumours block immune attack through a variety of mechanisms including inhibition of tumour-specific CTL and CD4 T cell activation and function (1). This is driven by tumour over-expression of PD-L1, interacting with tumour-specific T cell PD-1 receptor (2) and T cell energy induced by tumour-mediated T cell expression of CTLA-4 inhibitory receptor (4). In addition, tolerogenic DC drive Treg induction and expansion via CTLA-4 (3) and accumulation of Tregs then contributes to the immunosuppressive milieu of the TME.

B) After ICI therapy, there is re-activation and proliferation of tumour-specific CTLs via blockade of PD-1 axis (1), and return of functional cytotoxicity, resulting in perforin release and tumour cell killing (2). As tumour damage increases, the TME is disrupted allowing macrophages to deplete Tregs via FcR binding of anti-CTLA-4 antibody (3). Tumour antigen release is driven by immune lysis of tumour cells which are processed by conventional DC and presented to naive T cells in context of checkpoint inhibition of CTLA-4, enhancing CTL proliferation and function (4). Tumour damage and antigen release is also supplemented by concomitant use of conventional chemo/radiotherapy, which can reveal new tumour-associated antigens and contribute to anti-tumour immune responses (5).


Trial Name and/or Phase [Ref]	Trial Drugs (dose)	Patient Number	1-Year OS Rate (%)	18-Month OS Rate (%)	2-Year OS Rate (%)	Median OS (Months)
Phase III [76]	Ipi (3mg/kg) vs gp100 vaccine	676	45.6 vs 25.3	33.2 vs 16.3	23.5 vs 13.7	10.1 vs 6.4
Phase II [79]	Ipi (10mg/kg) + Budesonide vs Ipi (10mg/kg)	115	55.9 vs 62.4	N/R	40.5 vs 41.7	17.7 vs 19.3
Phase II [80]	Ipi (10 vs 3 vs 0.3mg/kg)	217	48.6 vs 39.3 vs 39.6	34.5 vs 30.2 vs 23.0	29.8 vs 24.2 vs 18.4	11.4 vs 8.7 vs 8.6
Phase II [81]	Ipi (10mg/kg)	226	47.2	39.4	32.8	10.2
KEYNOTE-006 Phase III [86, 87]	Pembro (10mg/kg every 2 weeks) vs Pembro (10mg/kg every 3 weeks) vs Ipi (3mg/kg every 3 weeks)	834	74.1 vs 68.4 vs 58.2	N/R	55.1 vs 55.3 vs 43.0	N/A vs N/A vs 16.0
Phase I [88, 89]	Pembro (1-10mg/kg)	104	62	N/R	43	16.8
Phase III [91]	Niv (3mg/kg) vs Dacarbazine (1000mg/m ²)	418	72.9 vs 42.1	N/A	N/A	N/A vs 10.8
Phase I [92, 93]	Cohort 1: Niv (0.3mg/kg) + Ipi (3mg/kg)	14	56	N/A	N/A	14.8
	Cohort 2: Niv (1mg/kg) + Ipi (3mg/kg)	17	94	N/A	N/A	N/R
	Cohort 2a: Niv (3mg/kg) + Ipi (1mg/kg)	16	89	N/A	N/A	N/R
	Cohort 3: Niv (3mg/kg) + Ipi (3mg/kg)	6	100	N/A	N/A	N/R
CHECKMATE 069 Phase II [94, 95]	Niv (1mg/kg) + Ipi (3mg/kg) vs Ipi (3mg/kg)	142	73.4 vs 64.8	N/R	63.8 vs 53.6	N/R
CHECKMATE 067 Phase III [96, 97]	Niv (3mg/kg)	316	N/A	N/A	59	37.6
	Niv (1mg/kg) + Ipi (3mg/kg), then Niv (3mg/kg) maintenance	314	N/A	N/A	64	N/A
	Ipi (3mg/kg)	315	N/A	N/A	45	19.9
CHECKMATE 064 Phase II [98]	Niv (3mg/kg), then Ipi (3mg/kg)	68	76	N/A	N/A	N/A
	Ipi (3mg/kg), then Niv (3mg/kg)	70	54	N/A	N/A	16.9

Table 1: Key clinical trials of ICIs in patients with malignant melanoma, and their associated survival data. Ipi, ipilimumab; Pembro, pembrolizumab; Niv, nivolumab; OS, overall survival; N/A, not available; N/R, not reported.

Trial name, Phase [Ref]	Disease	Trial Drugs (dose)	Patient Number	1-Year OS Rate (%)	Median OS (months)	Objective Responses Rate (%)	Median PFS (months)	Correlation Between Tumour PD-L1 Expression and Response?	Treatment-Related Adverse Events (grade≥3) (%)
CHECKMATE-063 Phase III [104]	Sq NSCLC	Niv (3mg/kg)	117	40.8	8.2	14.5	1.9	Yes	17
CHECKMATE-017 Phase III [102]	Sq NSCLC	Niv (3mg/kg) vs Docetaxel	272	42 vs 24	9.2 vs 6.0	20 vs 9	3.5 vs 2.8	N/R	7 vs 55
CHECKMATE-057 Phase III [103]	Non-Sq NSCLC	Niv (3mg/kg) vs Docetaxel	582	51 vs 39	12.2 vs 9.4	19 vs 12	2.3 vs 4.2	Yes	10 vs 54
KEYNOTE-001 Phase I [107]	NSCLC	Pembro (2-10mg/kg)	495	N/R	12.0	19.4	3.7	Yes	9.5
KEYNOTE-010 Phase II/III [105, 106]	>1% PD-L1+ NSCLC	Pembro (2mg/kg) vs Pembro (10mg/kg) vs Docetaxel	1034	43.2 vs 52.3 vs 34.6	10.4 vs 12.7 vs 8.5	N/R	3.9 vs 4.0 vs 4.9	Yes	13 vs 16 vs 35
KEYNOTE-024 Phase II [108]	>50% PD-L1+ NSCLC	Pembro (200mg) vs Docetaxel	305	N/R	N/R	44.8 vs 27.8	10.3 vs 6.0	High PD-L1 a prerequisite for inclusion in trial	26.6 vs 53.3
POPLAR Phase II [109]	NSCLC	Atezo (1200mg) vs Docetaxel	277	47.9 vs 37.8	12.6 vs 9.7	15 vs 15	2.7 vs 3.0	Yes	40 vs 53
OAK Phase III [110, 111]	NSCLC	Atezo vs Docetaxel	1225	55 vs 41	13.8 vs 9.6	14 vs 13	2.8 vs 4.0	Yes	37 vs 54
Phase 1b [112]	NSCLC	Durvalumab + Tremelimumab	102	N/R	N/R	0-23	N/R	N/R	36
CHECKMATE-012 Phase 1 [115]	NSCLC	Niv (3mg/kg) + Ipi vs Niv (3mg/kg) + Ipi	77	Not calculated vs 69	N/R	47 vs 38	8.1 vs 3.9	Yes	37 vs 33

Table 2: Key trials of ICIs targeting the PD-1 pathway in patients with non-small-cell lung cancer (NSCLC). Sq, Squamous; Non-Sq, non-squamous; Niv, nivolumab; Pembro, pembrolizumab; Atezo, atezolizumab; Ipi, ipilimumab; OS, overall survival; PFS, progression-free survival; N/R, not reported.

Figure 1



B

